Jubilant Pharmova Q1 FY27: revenue up 17% YoY, PAT down 45%

Ebitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹960.00

prior close

₹929.70

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+1.5% vs market

Pharmaceuticals peers, median of 164sector+0.1%+1.7% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

+0.1

15m

+1.4

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+0.2+1.5+0.1+1.7

Next day

-8.1-0.1-8.0-0.4-7.7

-7.4+0.1-7.5+0.1-7.5

-10.2-0.4-9.8-0.4-9.8

-9.9-0.2-9.7-0.9-9.0

-10.0+0.0-10.0-0.5-9.5

-9.9-0.0-9.9-1.0-8.9

15d

-6.0+0.1-6.1-0.6-5.5

+6.8-0.0+6.8+0.9+5.8

+0.5-3.1+3.6-3.1+3.6

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue rose 17.3% YoY to Rs 22,294 million in Q1 FY27, driven by Radiopharma and CDMO Sterile Injectables. However consolidated PAT fell 45% YoY to Rs 564 million from Rs 1,025 million. EBITDA margin compressed to about 12 percent from 15.9 percent YoY. Generics segment swung to a loss of Rs 101 million. Limited review by auditor Walker Chandiok was clean.

Likely market impact

Strong revenue growth is positive but sharp PAT fall and margin compression may weigh on the stock. Generics segment loss is a concern.